HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Rani Therapeutics Hldgs (NASDAQ:RANI) and maintains a $22 price target.
June 06, 2023 | 10:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reiterates a Buy rating on Rani Therapeutics Hldgs and maintains a $22 price target.
The reiterated Buy rating and maintained $22 price target by HC Wainwright & Co. analyst Mitchell Kapoor indicates a positive outlook for Rani Therapeutics Hldgs. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100